Johnson & Johnson Aktie News

Johnson & Johnson has increased its dividend each year for over half a century. The company has a very healthy financial profile.

PENSACOLA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- A U.S. District Court Special Master in the talc multidistrict litigation (MDL) against Johnson & Johnson (J&J) entered an Opinion, reaffirming that plaintiffs may present expert testimony supporting general causation to the jury.

Johnson & Johnson signed a deal to avoid tariffs. Although it faces other threats, it can overcome them.

Johnson & Johnson's MedTech segment saw its worldwide operational sales grow 5.4% year over year in 2025, reaching about $33.8 billion, the company said in a Wednesday (Jan. 21) earnings release. The segment slightly outpaced the healthcare solution provider's other segment, Innovative Medicine, whose worldwide operational sales were up 5.

Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript

Johnson & Johnson (NYSE:JNJ) reported fourth quarter and full-year 2025 results that came in above market expectations and issued 2026 guidance that was modestly ahead forecasts.  For Q4, Johnson & Johnson reported sales of $24.6 billion, representing reported growth of 9.1% year-over-year and operational growth of 7.1%.

Stock futures are slightly lower this morning after sinking on Tuesday owing to new tariff threats from President Donald Trump; investors are awaiting Trump's speech today at the World Economic Forum in Davos, amid ongoing tensions related to the president's efforts to acquire Greenland; Netflix stock is tumbling after the streaming giant released earnings and said it would pause stock buybacks...

Johnson & Johnson sees revenue grow 9% in the fourth quarter, amid strength in its cancer drugs.